Folge uns
DE
DE

Eines der Hauptziele von Life4me+ — ist neue Fälle von HIV und anderen STIs, Hepatitis C und Tuberkulose zu verhindern.

Die App hilft, eine Kommunikation zwischen Ärzten und HIV-positiven Menschen aufzubauen. Die App erlaubt Ihnen, einen Zeitplan für Ihre Medikamenteneinnahme bequem zu organisieren – dies geschieht über eine für Dritte nicht nachvollziehbare und personalisierte Erinnerung.

Alle Nachrichten

Archiv

✕
16 August 2018
6440
Trogarzo affects the restoration of immunity

Trogarzo affects the restoration of immunity

The results of the 3 phase clinical trials of ibalizumab confirmed that the agent not only reduces the level of replication of drug-resistant strains of HIV, but also has a beneficial effect on restoration of immunity. According to scientists at Yale University, the use ...
15 August 2018
6194
GSK was told about the results of studies of prospective two-component ART

GSK was told about the results of studies of prospective two-component ART

#ViiV Healthcare, a division of the British pharmaceutical company GlaxoSmithKline, spoke about the promising results of studies of innovative therapy against HIV of cabotegravir / rilpivirin, which will reduce the intake of necessary medications from a daily dose of three ...
13 August 2018
7662
In the United States approved a new type of female contraceptive

In the United States approved a new type of female contraceptive

The US Food and Drug Administration (FDA) last Friday, August 10, approved the use of the innovative female contraceptive Annovera (a combination of estrogen and segesterone acetate). The contraceptive is an intravaginal ring that can be used by women throughout the year. ...
10 August 2018
4120
Supercomputer modeling opens the door for developing new methods of HIV treatment, scientists

Supercomputer modeling opens the door for developing new methods of HIV treatment, scientists

In the middle of last week Nature published the results of a study that established that the naturally occurring compound inositol hexakisphosphate (IP6), involved in both assembly and maturation of HIV-1, could be the key to developing new methods of treating the virus.
1 August 2018
4882
The results of DolPHIN-1 are summarized: dolutegravir is better than efavirenz cures HIV in women at the extreme stages of pregnancy

The results of DolPHIN-1 are summarized: dolutegravir is better than efavirenz cures HIV in women at the extreme stages of pregnancy

#Dolutegravir demonstrated greater efficacy in suppressing HIV than efavirenz in late pregnancy, Dr. Saye Hu said at the 22nd International AIDS Conference (AIDS2018). According to him, the results of the DolPHIN-1 study showed that in pregnant women of HIV-positive women ...
31 Juli 2018
7120
Doravirin suppresses HIV more effectively than the combination of darunavir / ritonavir

Doravirin suppresses HIV more effectively than the combination of darunavir / ritonavir

An experimental non-nucleoside reverse transcriptase inhibitor (NNRTI), Doravirin, showed greater efficacy in suppressing the viral load of HIV than that of darunavir / ritonavir. These are the results of clinical studies of the 3 phases obtained after 96 weeks of observation ...
30 Juli 2018
5935
WHO has issued updated recommendations for the treatment of hepatitis C

WHO has issued updated recommendations for the treatment of hepatitis C

As the Coalition for Preparedness for Treatment (ITPCru) reported last week, in the end of July, on the eve of World Hepatitis Day, which was held this Saturday, the World Health Organization (WHO) prepared updated recommendations for the treatment of chronic hepatitis C.
26 Juli 2018
6405
Hormonal therapy may reduce the effectiveness of PrEP among transgender women

Hormonal therapy may reduce the effectiveness of PrEP among transgender women

Fear of side effects on the background of the interaction of feminizing hormonal therapy and PrEP can cause transgender women to refuse pre-exposure prophylaxis HIV, experts said at the 22nd International AIDS Conference (AIDS2018).
25 Juli 2018
7023
Scientists have announced the results of research PARTNER2

Scientists have announced the results of research PARTNER2

On the eve, July 24, at the International AIDS Conference in Amsterdam (AIDS2018), the results of a number of major studies in the field of HIV treatment and prevention were announced. Among them - data confirming the effectiveness of the strategy of "treatment as prevention" ...
25 Juli 2018
6918
A three-component regimen based on dolutegravir antiretroviral suppresses HIV more effectively than others

A three-component regimen based on dolutegravir antiretroviral suppresses HIV more effectively than others

An analysis of data from more than 100,000 Brazilian patients initiating antiretroviral therapy showed that those who received the three-component tenofovir / lamivudine / dolutegravir (TDF / ZTC / DTG) regimen achieved viral load faster than those receiving other regimens ...
Wir verwenden Cookies auf dieser Website, um den Besuch unserer Website attraktiv zu gestalten und die Nutzung bestimmter Funktionen zu ermöglichen.
Durch Klicken auf eine beliebige Schaltfläche auf dieser Website geben Sie Ihre Erlaubnis zur Verwendung von Cookies.